Legend Biotech

Legend Biotech is a global, commercial-stage biotechnology company headquartered in Somerset, New Jersey, with facilities in Piscataway, New Jersey; Nanjing, China; Dublin, Ireland; and Ghent, Belgium. The company focuses on developing, manufacturing, and commercializing novel therapies aimed at improving the lives of patients worldwide. Legend Biotech’s pipeline includes agents targeting both hematologic and solid tumors, with a strong commitment to cutting-edge cell therapies. The company employs over 1,000 individuals and has a strategic collaboration with Janssen Biotech, Inc. to develop and commercialize CARVYKTI® (ciltacabtagene autoleucel), a BCMA-targeted CAR-T cell therapy approved by the FDA and European Commission for the treatment of multiple myeloma. In March 2024, Legend Biotech published its inaugural Environmental, Social, and Governance (ESG) report, highlighting its focus on sustainability and robust governance. The company’s technology platforms include autologous and allogeneic CAR-T therapy, natural killer (NK) cells, and gamma-delta (γδ) T cells, and it is exploring non-gene-editing universal CAR-T technology. Legend Biotech has received multiple regulatory approvals and designations, including Breakthrough Therapy Designation and Orphan Drug Designation. The company is listed on the NASDAQ Biotechnology Index and is actively involved in strategic collaborations to advance its cell therapy platforms. Legend Biotech prioritizes efficiency, integrity, and a diverse workforce through strong environmental, health, and safety management.